Amyotrophic Lateral Sclerosis News and Research

RSS

CIRM awards Salk Institute $10.8M grant to develop stem-cell based therapy for Lou Gehrig's Disease

The Salk Institute has been awarded a $10.8 million grant by the California Institute for Regenerative Medicine (CIRM) for translational research focusing on developing a novel stem-cell based therapy for Amyotrophic Lateral Sclerosis (ALS) - or Lou Gehrig's Disease.

29 Oct 2009

Moores UCSD Cancer Center awarded $20 million for cancer research

Researchers led by Moores UCSD Cancer Center Director Dennis A. Carson, MD, professor of medicine, and Catriona Jamieson, MD, PhD, assistant professor of medicine and director of the Cancer Stem Cell Research Program at the Moores UCSD Cancer Center have been awarded $20 million over four years to develop novel drugs against leukemia stem cells.

28 Oct 2009

APC enzyme may be effective for treating amyotrophic lateral sclerosis

A chemical cousin of a drug currently used to treat sepsis dramatically slows the progression of amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, in mice. The results offer a bit of good news in efforts to develop a therapy to stop or slow the progression of a disease that generally kills its victims within just a few years.

26 Oct 2009

H.R. 3790 wins praises in Pennsylvania

The Pennsylvania Association of Medical Suppliers and the American Association for Homecare praised a bipartisan bill in Congress, H.R. 3790, to eliminate the misguided and deeply flawed "competitive" bidding program for durable medical equipment and services in Medicare. The bidding process in this controversial program began on October 21 in the Pittsburgh metropolitan statistical areas and seven other MSAs across the U.S.

23 Oct 2009

Bill eliminating the flawed medical equipment bidding process in the Riverside-San Bernardino area lauded

The California Association of Medical Product Suppliers and the American Association for Homecare praised a bipartisan bill in Congress, H.R. 3790, to eliminate the misguided and deeply flawed "competitive" bidding program for durable medical equipment and services in Medicare.

23 Oct 2009

Texas and U.S. homecare groups praise bipartisan bill; say bidding program may reduce quality patient care

The Texas Alliance for Home Care Services and the American Association for Homecare praised a bipartisan bill in Congress, H.R. 3790, to eliminate the deeply flawed "competitive" bidding program for durable medical equipment and services in Medicare.

23 Oct 2009

Amorfix Life Sciences signs sale and distribution agreement with Cedarlane Laboratories

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases, announced today that it has signed an agreement with Cedarlane Laboratories for the sale and distribution of Amorfix's proprietary antibodies and reagents.

22 Oct 2009

H.R. 3790 to reduce Medicare spending; preserve access to quality care

The Ohio Association of Medical Equipment Services and the American Association for Homecare praised a bipartisan bill in Congress, H.R. 3790, to eliminate the misguided, flawed "competitive" bidding program for durable medical equipment and services in Medicare.

22 Oct 2009

iPierian to participate in $3.7 million NIH grant awarded to The Johns Hopkins University

iPierian, Inc., a biopharmaceutical company focused on changing the paradigm of drug discovery and development through the application of cellular reprogramming, today announced that it has been selected to participate in a $3.7 million National Institutes of Health (NIH) Grand Opportunities (GO) grant awarded to The Johns Hopkins University.

22 Oct 2009

NIH awards $3.7 million to Johns Hopkins scientists for research on stem cells developed from ALS patients' skin

Johns Hopkins scientists have been awarded a $3.7 million grant from the National Institutes of Health (NIH) to learn more about the nerve and muscle-wasting disease amyotrophic lateral sclerosis (ALS) using stem cells developed from ALS patients' skin. The award, given over a two-year span, will be shared with three other laboratories, including one at Harvard University and two at Columbia University.

22 Oct 2009

American Association for Homecare commends bipartisan lawmakers

The American Association for Homecare praised a bipartisan group of lawmakers in the House of Representatives for backing introduction of H.R. 3790, a bill to eliminate the controversial, deeply flawed "competitive" bidding program for durable medical equipment and services in Medicare.

21 Oct 2009

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

AVANIR Pharmaceuticals, Inc. today announced detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS).

14 Oct 2009

Discovery opens new possibility of designing drugs for amyotrophic lateral sclerosis

Researchers at Lund University, Sweden, have taken a snapshot of proteins changing shape, sticking together and creating structures that are believed to trigger deadly processes in the nervous system. The discovery opens the possibility of designing drugs for a devastating neurological disease, ALS.

13 Oct 2009

New mouse models resembles human ALS; may provide important tool for screening new drugs

A new mouse model of amyotrophic lateral sclerosis (ALS) closely resembles humans with the paralyzing disorder, researchers at Washington University School of Medicine in St. Louis report.

13 Oct 2009

Mouse model of ALS closely resembles humans with the paralyzing disorder, says report

A new mouse model of amyotrophic lateral sclerosis (ALS) closely resembles humans with the paralyzing disorder, researchers at Washington University School of Medicine in St. Louis report.

13 Oct 2009

Guidelines for treating amyotrophic lateral sclerosis identified

New guidelines from the American Academy of Neurology identify the most effective treatments for amyotrophic lateral sclerosis (ALS), often called Lou Gehrig's disease. The guidelines are published in the October 13, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology.

13 Oct 2009

Wake Forest University School of Medicine honours researchers

Wake Forest University School of Medicine honored eight of its researchers with awards for excellence at the 13th Annual Research Awards Day Oct. 1.

12 Oct 2009

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo

9 Oct 2009

RXi Pharmaceuticals presents new preclinical data from its advanced RNAi therapeutic platform

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced the presentation of new preclinical data from its advanced RNAi therapeutic platform at its Annual Investor Event held in New York City on Monday, October 5, 2009.

9 Oct 2009

Premature aging of immune system develops amyotrophic lateral sclerosis

Premature aging of the immune system appears to play a role in the development of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, according to research scientists from the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai Medical Center, the Weizmann Institute of Science in Israel, and Sheba Medical Center in Israel.

9 Oct 2009

Amyotrophic Lateral Sclerosis News and Research

CIRM awards Salk Institute $10.8M grant to develop stem-cell based therapy for Lou Gehrig's Disease

Moores UCSD Cancer Center awarded $20 million for cancer research

APC enzyme may be effective for treating amyotrophic lateral sclerosis

H.R. 3790 wins praises in Pennsylvania

Bill eliminating the flawed medical equipment bidding process in the Riverside-San Bernardino area lauded

Texas and U.S. homecare groups praise bipartisan bill; say bidding program may reduce quality patient care

Amorfix Life Sciences signs sale and distribution agreement with Cedarlane Laboratories

H.R. 3790 to reduce Medicare spending; preserve access to quality care

iPierian to participate in $3.7 million NIH grant awarded to The Johns Hopkins University

NIH awards $3.7 million to Johns Hopkins scientists for research on stem cells developed from ALS patients' skin

American Association for Homecare commends bipartisan lawmakers

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

Discovery opens new possibility of designing drugs for amyotrophic lateral sclerosis

New mouse models resembles human ALS; may provide important tool for screening new drugs

Mouse model of ALS closely resembles humans with the paralyzing disorder, says report

Guidelines for treating amyotrophic lateral sclerosis identified

Wake Forest University School of Medicine honours researchers

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

RXi Pharmaceuticals presents new preclinical data from its advanced RNAi therapeutic platform

Premature aging of immune system develops amyotrophic lateral sclerosis

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News